Changing the Status Quo of Traditional Drug Development

 

Our technology allows deeper insight into the effects and potential treatments of metabolic diseases to mitigate impact on human health and streamline the translation from R&D to clinical trials.

 
 

our technology

ObaCell®: Empowering research with adipose tissue models that incorporate human diversity and mimic human biology.

Learn more

our vision

We envision a world where enriched preclinical insights create future therapies that are accessible, equitable, and effective for patients worldwide regardless of demographic and socioeconomic backgrounds.

Learn More

Our Partners

Our strategic partnerships with distinguished industry leaders not only enhance our company's capabilities but also foster innovation, synergy, and collective success through collaborative efforts.

LEARN MORE

Our investors

The unwavering support of our investors not only ensures stability but also propels our company towards greater innovation, enabling us to bring our vision closer to reality with every milestone achieved.

LEARN MORE

Publications

International Journal of Molecular sciences

Adipose Tissue in Breast Cancer Microphysiological Models to Capture Human Diversity in Preclinical Models

STem cells international

Human Adipose Derived Cells in Two- and Three-Dimensional Cultures: Functional Validation of an In Vitro Fat Construct

advanced biology

Biomechanical and Biological Characterization of XGel, a Human-Derived Hydrogel for Stem Cell Expansion and Tissue Engineering

Posters

MPS World SUmmit 2024

ObaCell® Obesity-on-a-Chip, a Platform for Disease Modeling and Drug Development- AI Image Analysis and a GLP-1 Agonist Study

MPS World Summit 2024

Human-derived Biomaterials to Fully Support Microphysiological Systems

AACR 2023

A Patient Derived Xenograft Model for Lung Adenocarcinoma Using ObaGel®, a Human Derived Hydrogel

Distributors

 
 

SUBSCRIBE

Sign up with your email address to receive our monthly newsletter.